Valuation: VISEN Pharmaceuticals

Market Cap 1.88B 278M 243M 224M 206M 391M 26.75B 397M 2.68B 1.05B 13.08B 1.04B 1.02B 45.07B P/E 2026 *
-18.4x
P/E 2027 * -30.8x
Enterprise Value 1.62B 239M 209M 193M 177M 336M 23.03B 342M 2.3B 904M 11.25B 899M 879M 38.79B EV / Sales 2026 *
23.9x
EV / Sales 2027 * 4.21x
Free-Float
19.09%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 06/11/2018
Director of Finance/CFO 42 12/10/2025
Chief Tech/Sci/R&D Officer 54 31/03/2020
Director TitleAgeSince
Director/Board Member 53 31/03/2021
Director/Board Member 60 31/03/2021
Director/Board Member 58 26/08/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 278M
-0.17%+1.47%+3.16%+7.43% 50.35B
-0.04%-2.27%+390.52%+596.97% 39.32B
+0.44%+2.23%+32.12%-5.89% 34.69B
+1.29%+2.98%+15.27%+57.08% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+0.64%-3.52% - - 16.49B
-1.11%-0.28%+69.64%+114.46% 15.31B
+0.43%+3.34%+14.96%+17.98% 13.8B
+1.52%+2.77%+16.81%-30.60% 12.87B
Average +0.44%-0.41%+68.34%+98.10% 27.06B
Weighted average by Cap. +0.42%-0.32%+82.59%+122.99%

Financials

2026 *2027 *
Net sales 67.73M 10M 8.75M 8.07M 7.42M 14.05M 963M 14.29M 96.33M 37.8M 471M 37.57M 36.75M 1.62B 447M 66.08M 57.77M 53.3M 48.99M 92.83M 6.36B 94.42M 636M 250M 3.11B 248M 243M 10.71B
Net income -99M -14.62M -12.78M -11.79M -10.84M -20.54M -1.41B -20.89M -141M -55.24M -688M -54.91M -53.71M -2.37B -58M -8.57M -7.49M -6.91M -6.35M -12.03M -824M -12.24M -82.48M -32.36M -403M -32.17M -31.47M -1.39B
Net Debt -262M -38.74M -33.87M -31.25M -28.72M -54.43M -3.73B -55.36M -373M -146M -1.82B -145M -142M -6.28B 486K 71.79K 62.77K 57.9K 53.23K 101K 6.91M 103K 691K 271K 3.38M 270K 264K 11.64M
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
82
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.27CNY
Average target price
44.50CNY
Spread / Average Target
+157.71%

Annual profits - Rate of surprise